MUFG Americas’s Travere Therapeutics TVTX Stock Holding History

MUFG Americas’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-630	Closed	-$17K	–	839
2018 Q2	$17K	Hold	630	–	–	﹤0.01%	692
2018 Q1	$14K	Sell	630 -200	-24%	-$4.76K	﹤0.01%	724
2017 Q4	$17K	Buy	+830	New	+$19K	﹤0.01%	777
2015 Q4	–	Sell	-210	Closed	-$4K	–	1205
2015 Q3	$4K	Buy	+210	New	+$6.22K	﹤0.01%	1007

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MUFG Americas's TVTX Position: Q3 2018 in Review

MUFG Americas sold out of Travere Therapeutics (TVTX) in Q3 2018, closing a stake of 630 shares — an estimated $17K sold.

MUFG Americas first reported a position in TVTX in Q3 2015 and held it in 4 quarters. The position peaked at $17K in Q2 2018. 128 funds tracked by Wall St. Rank hold TVTX as of Q3 2018.

MUFG Americas reported no remaining Travere Therapeutics position as of Q3 2018 after selling out during the quarter.
MUFG Americas sold 630 Travere Therapeutics shares in Q3 2018, an estimated $17K.
MUFG Americas first reported a position in Travere Therapeutics in Q3 2015 and held it in 4 quarters.
MUFG Americas's Travere Therapeutics position peaked at $17K in Q2 2018.
128 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2018.

Based on MUFG Americas's 13F filing for Q3 2018, filed 14 Nov 2018.